書籍詳細

1. 日本人の2型糖尿病とグリニドの役割

P.16 掲載の参考文献

• 1) Gerich JE:Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 51 Suppl 1:S117-121, 2002

• 2) 小坂樹徳:糖尿病におけるインスリン初期分泌反応. Diabetes Frontier 6:7-22, 1995

• 3) Welch S et al:Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508-1518, 1990
  pubmed

• 4) Kim H et al:Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 16:804-809, 2010
  pubmed

• 5) Bergman RN et al:Accurate assessment of beta-cell function:the hyperbolic correction. Diabetes 51 Suppl 1:S212-220, 2002

• 6) Taniguchi A et al:Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes 41:1540-1546, 1992
  pubmed

• 7) DeFronzo RA:Lilly lecture 1987. The triumvirate:beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988
  pubmed

• 8) Tanaka Y et al:Interesting insulin response to oral glucose load in young Japanese subjects with glucose tolerance. Diabetes Care 23:710-712, 2000
  pubmed

• 9) DeFronzo RA et al:Determinants of glucose tolerance in glucose tolerance at baseline in the Actos Now for Prevention of Diabetes(ACT NOW)study. Diabetologia 53:435-445, 2010
  pubmed

• 10) Kawamori R et al:Voglibose for prevention of type 2 diabetes mellitus:arandomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:1607-1614, 2009
  pubmed

• 11) Kawamori R:Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract 40 Suppl:S35-42, 1998

• 12) Jensen CC et al:Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U. S. Diabetes 51:2170-2178, 2002

• 13) 清野裕:日本人糖尿病特徴とインスリン分泌異常. Medical Science Digest 30:248-250, 2004

• 14) 河盛隆造:薬物療法-αGIをどう使うか-. 治療 92:643-651, 2010
  Medical*Online

P.25 掲載の参考文献

• 1) Shinkai H et al:N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. J Med Chem 31:2092-2097, 1988
  pubmed

• 2) 長嶋一昭, 清野 裕:糖尿病治療の進歩と新展開 新しい薬物療法. 糖尿病学の進歩2004, pp71-75

• 3) Ichikawa K et al:Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line. Arzneimittelforschung 52:605-609, 2002

• 4) Fujitani S, Yada T:Anovel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx. Endocrinology 134:1395-1400, 1994

• 5) Hansen AM et al:Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 51:2789-2795, 2002
  pubmed

• 6) Lins L et al:Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family. Biochem Pharmacol 50:1879-1884, 1995
  pubmed

• 7) Kawai J et al:Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment. Biochem J 412:93-101, 2008
  pubmed

• 8) Fujitani S et al:The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition. Br J Pharmacoｌ 120:1191-1198, 1997
  pubmed

• 9) Mukai E et al:Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells. Am J Physiol 274:E38-44, 1998
  pubmed

P.31 掲載の参考文献

• 1) Igarashi Y et al:Characteristics of Japanese sublects who progress from normal to glucose tolerance. Longitudinal study excluding changes in body weight. Endocr J 52:683-689, 2005

• 2) Hirose T et al:The effects of Nateglinide following oral glucose load in impaired glucose tolerance subjects:Rapid insulin stimulation by Nateglinide in IGT subjects. Endocr J 49:649-652, 2002
  pubmed

• 3) Uchino H et al:Impairment of early insulin response after glucose load rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes:assessment using nateglinide, a new insulin secretagogue, Endocr J 47:639-641, 2000
  pubmed

• 4) Esposite K et al:Atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219, 2004

• 5) Otsuka A et al:Temporal hyperglycemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia 48:2667-2674, 2005

• 6) Tanaka A et al:Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun 350:195-201, 2006
  pubmed

• 7) Miwa S et al:Efficacy and safety of once daily gliclazide(20mg/day) compared with nateglinide. Endocr J 51:393-398, 2004

2. グリニドの膵外作用とその評価

P.35 掲載の参考文献

• 1) Iso H et al:Serum triglycerides and risk of coronary heart disease among Japanease men and women. Am J Epidemiol 153:490-499, 2001

• 2) Mori Y et al:Role of early insulin secretion in post-glucose loading hyperglycemia and post-fat loading hyperlipidemia:comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes Metab 6:422-431, 2004

• 3) Mori Y et al:Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine 29:309-315, 2006
  pubmed

• 4) Mori Y et al:Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine 23:39-43, 2004
  pubmed

• 5) Mine T et al:Nateglinide suppresses postprandial hypertriglyceridemia in Zucker Fatty rats and Goto-Kakizaki rats:comparison with voglibose and glibenclamide. Biol Pharm Bulｌ 25:1412-1416, 2002
  pubmed

• 6) 三根智幸ほか:高脂肪食摂取による肝中性脂肪蓄積に対するナテグリニドの効果の検討. Prog Med 25:1125-1132, 2005
  Medical*Online

• 7) Mori Y et al:Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test. Endocrine 25:203-206, 2004
  pubmed

• 8) Ai M et al:Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes. Diabetes Care 29:1180, 2006
  pubmed

• 9) Hong-wei GAO et al:Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin 28:534-539, 2007
  pubmed

• 10) Dimitriadis G et al:Restoration of early insulin secretion after a meal in type 2 diabetes:effects on lipid and glucose metabolism. Eur J Clin lnves 34:490-497, 2004

• 11) Vakkilainen J et al:Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 18:484-490, 2002
  pubmed

• 12) Johanson EH et al:No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes Metab Res Rev 21:376-381, 2005
  pubmed

P.40 掲載の参考文献

• 1) Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology:Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999

• 2) Otsuka A et al:Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia 48:2667-2674, 2005
  pubmed

• 3) Shimabukuro M et al:Asingle dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients. Diabet Med 21:983-986, 2004

• 4) Tentolouris N et al:Acute nateglinide administration in subjects with type 2 diabetes:effects on postprandial metabolism, coagulation, and fibrinolysis. Nutr Metab Cardiovasc Dis 15:6-12, 2005
  pubmed

• 5) Esposito K et al:Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219, 2004
  pubmed

• 6) Monnier L et al:Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:variations with increasing levels of HbA(1c). Diabetes Care 26:881-885, 2003

• 7) Mita T et al:Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 27:2456-2462, 2007
  pubmed

P.45 掲載の参考文献

• 1) Mitrakou A et al:Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-1390, 1990
  pubmed

• 2) Firth RG et al:Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. J Clin Invest 77:1525-1532, 1986
  pubmed

• 3) Uchino H et al:Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes:assessment using nateglinide, a new insulin secretagogue. Endocr J 47:639-641, 2000
  pubmed

• 4) Cherrington AD:Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214, 1999
  pubmed

• 5) Pagliassotti MJ et al:Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. J Clin Invest 97:81-91, 1996
  pubmed

• 6) Mine T et al:Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet. Metabolism 57:140-148, 2008
  pubmed

• 7) Morita Y et al:Nateglinide is useful for nonalcoholic steatohepatitis(NASH)patients with type 2 diabetes. Hepatogastroenterology 52:1338-1343, 2005
  pubmed

P.50 掲載の参考文献

• 1) Nishikawa T et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
  pubmed

• 2) Kashiwagi A et al:Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol Endocrinol Metab 277:976-983, 1999

• 3) Nomiyama T et al:Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia 45:1577-1583, 2002
  pubmed

• 4) Nomiyama T:Accumulation of Somatic Mutation in Mitochondrial DNA and Atherosclerosis in Diabetic Patients. Ann NY Acad Sci 1011:193-204, 2004
  pubmed

• 5) Nomiyama T et al:The polymorphism manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 Diabetic Patients. J Hum Genet 48:138-141, 2003
  pubmed

• 6) Nishikawa T et al:Evaluation of Urinary 8-Hydroxydeoxy-Guanosine as a Novel Biomarker of Macrovascular Complications in Type 2 Diabetes. Diabetes Care 26:1507-1512, 2003
  pubmed

• 7) Assaloni R et al:Effects of S21403(mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48:1919-1924, 2005
  pubmed

• 8) Ceriello A et al:Postprandial Hyperglycemia and Diabetes Complications. Is It Time to Treat? Diabetes 54:1-7, 2005
  pubmed

• 9) Nomiyama T et al:Reduction of insulin-stimulated glucose uptake by peroxynitrite is concurrent with tyrosine nitration of insulin receptor substrate-1. Biochem Biophys Res Commun 320:639-647, 2004
  pubmed

• 10) Charbonneau A et al:lnducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice:potential role of tyrosine nitration of insulin signaling proteins. Diabetes 59:861-871, 2010
  pubmed

• 11) Li Y et al:Effect of short-term therapy with different insulin secretagogues on gltlcose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. Diabetes Res Clin Pract 88:42-47, 2010
  pubmed

• 12) Gumieniczek A et al:Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. Pharmacol Res 52:162-166, 2005
  pubmed

• 13) Gumieniczek A:Modification of cardiac oxidative stress in alloxan-induced diabetic rabbits with repaglinide treatment. Life Sci 78:259-263, 2005
  pubmed

3. 大規模臨床試験 NAVIGATOR

P.57 掲載の参考文献

• 1) Knowler WC et al:Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403, 2002
  pubmed

• 2) Chiasson JL et al:STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359(9323):2072-2077, 2002

• 3) Gerstein HC et al:Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:arandomised controlled trial. Lancet 368(9541):1096-1105, 2006

• 4) Holman RR et al:Eiifect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362(16):1463-1476, 2010
  pubmed

• 5) McMurray JJ et al:Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362(16):1477-1490, 2010
  pubmed

4. グリニドの使い方

P.62 掲載の参考文献

• 1) Taki H et al:Postmarketing study of nateglinide in Japan:treatment of medication-naive patients with type 2 diabetes. Adv Ther 22:621-635, 2005
  pubmed

• 2) 寺田央:2型糖尿病に対するナテグリニドの長期投与における二次無効および安全性についての検討. 臨床と研究 82:383-388, 2005
  Medical*Online

• 3) 田中俊一ほか:2型糖尿病患者に対する速効性・短時間作用型インスリン分泌促進剤ミチグリニドの長期投与試験. 薬理と治療 35:S-23-S-37, 2007

P.73 掲載の参考文献

• 1) Yulia H et al:Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 23:349-353, 2000

• 2) Horton ES et al:Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose level in type 2 diabetes. Diabetes Care 23:1660-1665, 2000
  pubmed

• 3) Marre M et al:Nateglinide improves glycemic control when added to metformin monotherapy:results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 4:177-186, 2000

• 4) Schwarz SL et al:Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naTve elderly patients with type 2 diabetes. Diabetes Obes Metab 10:652-660, 2008
  pubmed

• 5) 菊池方利ほか:塩酸メトホルミン単独療法で血糖管理不十分な2型糖尿病患者に対するナテグリニドと塩酸メトホルミン併用の臨床効果-二重盲検群間比較法を用いた用量反応試験-. 臨床医薬 24(8):717-739, 2008
  Medical*Online

• 6) Julio R et al:Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 25:1529-1533, 2002

• 7) Fonseca V et al:Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 26:1685-1690, 2003
  pubmed

• 8) 菊池方利ほか:塩酸メトホルミン単独療法で血糖管理不十分な2型糖尿病患者に対するナテグリニドと塩酸メトホルミン併用の臨床効果-第II/III相二重盲検群間比較試験-. 臨床医薬 25(1):35-56, 2009

• 9) Ward AJ et al:Health and economic impact of combining metformin with nateglinide to achieve glycemic control:Comparison of the lifetime costs of complication in the U.K. Cost Eff Resour Alloc 2:2, 2004

P.79 掲載の参考文献

• 1) Nauck M et al:Reduced incretin effect in type 2(non-insulin-dependent) diabetes. Diabetologia 29:46-52, 1986
  pubmed

• 2) Ahren B:Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Disc 8:369-385, 2009

• 3) Drucker DJ:The biology of incretin hormones. Cell Metab 3:153-165, 2006
  pubmed

• 4) Yamazaki K et al:Effects of the Combination of a Dipeptidyl Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats. J Pharmacol Exp Ther 320:738-746, 2007

P.85 掲載の参考文献

• 1) Yoshihara T et al:Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 53(1):67-72, 2006
  pubmed

• 2) Kumashiro N et al:Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 54(1):163-166, 2007
  pubmed

• 3) Dashora UK et al:Insulin glargine in combination with nateglinide in people with Type 2 diabetes:a randomized placebo-controlled trial. Diabet Med 24(4):344-349, 2007
  pubmed

• 4) Juurinen L et al:Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes. Diabet Med 26(4):409-415, 2009
  pubmed

P.89 掲載の参考文献

• 1) Holman RR et al:Elifect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463-1476, 2010
  pubmed

• 2) Mita T et al:Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 27:2456-2462, 2007
  pubmed

• 3) Patel A et al:Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial. Lancet 370:829-840, 2007

• 4) Gerstein HC et al:Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes(ACCORD)trial. Am J Cardiol 99:34i-43i, 2007
  pubmed

• 5) Duckworth W et al:Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139, 2009
  pubmed

• 6) Fonseca VA et al:Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus. Metabolism 53:1331-1335, 2004
  pubmed

• 7) Mori Y et al:Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading:results of glucose loading on 2 consecutive days. Diabetes Obes Metab 7:182-188, 2005
  pubmed

• 8) Kurebayashi S et al:Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. Endocr J 53:213-217, 2006

• 9) Elliott WJ et al:Incident diabetes in clinical trials of antihypertensive drugs:a network meta-analysis. Lancet 369:201-207, 2007
  pubmed

• 10) Lewis EJ et al:Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
  pubmed

• 11) Kamoi K et al:Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care 25:2218-2223, 2002
  pubmed

• 12) de Simone G et al:Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 28:353-360, 2010
  pubmed

• 13) Movahed MR et al:Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 105:315-318, 2005

• 14) Nichols GA et al:Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 32:1851-1856, 2009
  pubmed

• 15) Madrid AH et al:Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation:a prospective and randomized study. Circulation 106:331-336, 2002
  pubmed

• 16) Holman RR et al:10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008
  pubmed

• 17) Holman RR et al:Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565-1576, 2008
  pubmed

• 18) Colhoun HM et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
  pubmed

5. 低血糖・体重増加

P.95 掲載の参考文献

• 1) Taki H et al:Study of nateglinide in Japan:long-term treatment of patients with type 2 diabetes. Adv Ther 23:307-324, 2006
  pubmed

• 2) Nagai T et al:Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 59:191-194, 2003
  pubmed

• 3) Sherk DK et al:Octreotide therapy for nateglinide-induced hypoglycemia. Ann Emerg Med 50:745-746, 2007
  pubmed

• 4) Nakayama S et al:Hypoglycemia following a nateglinide overdose in a suicide attempt. Diabetes Care 28:227-228, 2005

• 5) 小野吹美ほか:健康成人におけるミチグリニド服用時間の検討-服用時間の遅れが血糖・インスリン分泌パターンに与える影響-. プラクティス 24(1):79-84, 2007
  Medical*Online

6. 禁忌・慎重投与

P.102 掲載の参考文献

• 1) 池上孝雄, 近藤信雄:速効短時間型血糖降下薬ナテグリニド (ファスティック(R), スターシス(R)) の薬効薬理. 日薬理誌 116:171-181, 2000
  Medical*Online

• 2) 生島一真ほか:新規速効型インスリン分泌促進薬ミチグリニドカルシウム水和物 (グルファスト(R)錠) の薬理学的特徴および臨床試験成績. 日薬理誌 124:245-255, 2004

• 3) 能登谷洋子, 菊池方利:非スルホニル尿素系インスリン分泌促進薬の適応と使用法の実際. 診断と治療 91:144-148, 2003

• 4) Kurebayashi S et al:Efficacy and Adverse Effect of Nateglinide in Early Type 2 Diabetes. Comparison with Voglibose in a Cross-over Study. Endocr J 53:213-217, 2006

• 5) 伊藤直人ほか:腎不全期糖尿病患者の血糖コントロールにおけるナテグリニドの使用経験. Diabetes Frontier 13:803-807, 2002
  Medical*Online

• 6) Abe M et al:Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 57(7):579-586, 2010
  pubmed

• 7) Yale JF:Oral antihyperglycemic agents and renal disease:new agents, new concepts. J Am Soc Nephrol 16(Suppl 1):S7-10, 2005

• 8) Del Prato S et al:Treatment of Patient Over 64 Years of Age With Type 2 diabetes:experience from nateglinide pooled detabase retrospective analysis. Diabetes Care 26:2075-2080, 2003
  pubmed

• 9) 瀧 宏登ほか:高齢者糖尿病に対する速効型食後血糖降下剤ナテグリニド (ファスティック(R), スターシス(R)) の有効性および安全性について. Geriat Med 44(3):405-408, 2006

• 10) Ikenoue T et al:Hypoglycaemic and insulinotropic effects of anobel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane-carbonyl)-D-phenylalamine(A-4166). Br J Pharmacol 120:137-145, 1997

• 11) Scheen AJ:Drug-drun and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokiner 46(2):93-108, 2007
  pubmed

• 12) Taki H et al:Study of NategIinide in Japan:Long-Term Treatment of Patients With Type 2 Diabetes. Adv Ther 23(2):307-324, 2006
  pubmed